Profit before interest, taxes and amortization: Vor Biopharma (VOR)

Public company logo of Vor Biopharma (VOR)

Vor Biopharma Inc. (VOR) is developing a unique cellular technology that ensures global reach with minimal costs. The operating profit (EBIT) trend on GURU.Markets contains data where 0.00 captures the value of this parameter. Debt optimization relies on the commercialization of modified stem cells and strict adherence to temperature controls during the transport of genetic materials via certified operators.

vorbio.com (VOR) Operating profit EBITDA: for the period 11/23/2025 - 11/11/2026

Summary analytical data breakdowns for Vor Biopharma (VOR)

- stock price and consensus target price:
Price Chart Vor Bio Inc.|VOR - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Vor Biopharma|VOR - Total Company Value
- book capitalization data:
Net Asset Value per Share Vor Biopharma|VOR - Book Capitalization|Capitalization to Book Value Ratio vorbio.com|VOR - Cumulative Company Assets
- debt level and financial liquidity data:
Debt to Equity Vor Biopharma Inc.|VOR - Long-Term Debt to Equity|Current Liabilities to Capital Vor Biopharma, Inc.|VOR - Company Debts|Debt to Net Assets Ratio Vor Biopharma|VOR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Vor Biopharma|Quick Liquidity vorbio.com
- earnings and market multiples details:
VOR - Net Profit|Company Profit Forecast Vor Biopharma Inc.|VOR - Price to Earnings Ratio|Projected Price to Earnings Ratio vorbio.com|VOR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Vor Biopharma|VOR - Operating profit EBITDA|Earnings per share for the trailing year Vor Biopharma|VOR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth vorbio.com|VOR - Earnings per share growth in current year|Expected earnings per share trend next year Vor Biopharma Inc.
Analysis of all company metrics:Vor Bio Inc.
Manufactured products of Vor Biopharma Inc.

Analyzing the resilience of Vor Biopharma Inc. (VOR) to market shocks requires an assessment of the actual cash flow derived from the development of shielded stem cells for leukemia therapy. The EBITDA growth trajectory reflects daily operating income before taxes and interest, allowing investors to differentiate organic business scaling within the B2B segment from temporary liquidity inflows that may mask a decline in operational efficiency.

Competitor analysis for Vor Biopharma Inc.

TG Pharma - Profit before payment of interest, taxes and amortization|ACLX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization discmedicine.com|Syndax Pharmaceuticals, Inc. (SNDX) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kura Oncology Inc (KURA)|ADCT (ADC Therapeutics Corp) - Operating profit EBITDA|Operating profit before amortization FHTX (Foghorn)|Operating profit before deduction of amortization NKTX (Nkarta, Inc.)|Profit before payment of interest, taxes and amortization COEP (coeptistx.com)|Profit before payment of interest, taxes and amortization Actinium Pharmaceuticals, Inc. ATNM|Estrella Immunopharma Inc (ESLA) - Profit before interest, taxes and amortization|CASI - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization MRKR (Marker Therapeutics)|INAB (IN8bio, Inc.) - Operating profit before deduction of amortization|Eterna Therapeutics Inc. - Income before deduction of interest, taxes and amortization|GTBP (GT Biopharma) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization APTO|Operating profit EBITDA BPTH|Operating income before deduction of amortization MEI Pharma Corporation|Profit before payment of interest, taxes and amortization Vincerx Pharma VINC